vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与WORKIVA INC（WK）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是WORKIVA INC的1.7倍（$406.6M vs $238.9M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 4.9%，领先55.5%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 19.5%），BIOCRYST PHARMACEUTICALS INC自由现金流更多（$291.2M vs $50.7M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 16.6%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Workiva Inc.是一家全球知名的SaaS企业，主打云原生关联报告合规平台，支持关联数据调用与报告流程自动化，可广泛应用于财务、会计、风险及合规等多个业务场景，助力企业提升运营效率与合规管理水平。
BCRX vs WK — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $238.9M |
| 净利润 | $245.8M | $11.8M |
| 毛利率 | 97.7% | 80.7% |
| 营业利润率 | 64.0% | 3.3% |
| 净利率 | 60.5% | 4.9% |
| 营收同比 | 209.1% | 19.5% |
| 净利润同比 | 1017.5% | 234.0% |
| 每股收益（稀释后） | $1.13 | $0.21 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $406.6M | $238.9M | ||
| Q3 25 | $159.4M | $224.2M | ||
| Q2 25 | $163.4M | $215.2M | ||
| Q1 25 | $145.5M | $206.3M | ||
| Q4 24 | $131.5M | $199.9M | ||
| Q3 24 | $117.1M | $185.6M | ||
| Q2 24 | $109.3M | $177.5M | ||
| Q1 24 | $92.8M | $175.7M |
| Q4 25 | $245.8M | $11.8M | ||
| Q3 25 | $12.9M | $2.8M | ||
| Q2 25 | $5.1M | $-19.4M | ||
| Q1 25 | $32.0K | $-21.4M | ||
| Q4 24 | $-26.8M | $-8.8M | ||
| Q3 24 | $-14.0M | $-17.0M | ||
| Q2 24 | $-12.7M | $-17.5M | ||
| Q1 24 | $-35.4M | $-11.7M |
| Q4 25 | 97.7% | 80.7% | ||
| Q3 25 | 98.6% | 79.3% | ||
| Q2 25 | 98.3% | 77.0% | ||
| Q1 25 | 96.9% | 76.6% | ||
| Q4 24 | 95.4% | 77.1% | ||
| Q3 24 | 97.3% | 76.5% | ||
| Q2 24 | 98.4% | 76.8% | ||
| Q1 24 | 98.6% | 76.4% |
| Q4 25 | 64.0% | 3.3% | ||
| Q3 25 | 18.6% | -1.5% | ||
| Q2 25 | 18.2% | -10.3% | ||
| Q1 25 | 14.6% | -12.0% | ||
| Q4 24 | -3.4% | -6.7% | ||
| Q3 24 | 6.6% | -11.7% | ||
| Q2 24 | 8.0% | -13.0% | ||
| Q1 24 | -15.6% | -10.4% |
| Q4 25 | 60.5% | 4.9% | ||
| Q3 25 | 8.1% | 1.2% | ||
| Q2 25 | 3.1% | -9.0% | ||
| Q1 25 | 0.0% | -10.4% | ||
| Q4 24 | -20.4% | -4.4% | ||
| Q3 24 | -12.0% | -9.2% | ||
| Q2 24 | -11.6% | -9.9% | ||
| Q1 24 | -38.1% | -6.7% |
| Q4 25 | $1.13 | $0.21 | ||
| Q3 25 | $0.06 | $0.05 | ||
| Q2 25 | $0.02 | $-0.35 | ||
| Q1 25 | $0.00 | $-0.38 | ||
| Q4 24 | $-0.13 | $-0.15 | ||
| Q3 24 | $-0.07 | $-0.31 | ||
| Q2 24 | $-0.06 | $-0.32 | ||
| Q1 24 | $-0.17 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $338.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-119.2M | $-5.4M |
| 总资产 | $514.2M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $274.7M | $338.8M | ||
| Q3 25 | $212.9M | $315.9M | ||
| Q2 25 | $260.0M | $284.3M | ||
| Q1 25 | $295.1M | $242.0M | ||
| Q4 24 | $320.9M | $301.8M | ||
| Q3 24 | $96.8M | $248.2M | ||
| Q2 24 | $78.4M | $267.9M | ||
| Q1 24 | $84.3M | $296.1M |
| Q4 25 | $-119.2M | $-5.4M | ||
| Q3 25 | $-387.9M | $-36.9M | ||
| Q2 25 | $-421.6M | $-66.5M | ||
| Q1 25 | $-451.9M | $-75.7M | ||
| Q4 24 | $-475.9M | $-41.7M | ||
| Q3 24 | $-468.6M | $-50.8M | ||
| Q2 24 | $-475.6M | $-77.7M | ||
| Q1 24 | $-476.2M | $-83.2M |
| Q4 25 | $514.2M | $1.5B | ||
| Q3 25 | $446.4M | $1.4B | ||
| Q2 25 | $457.2M | $1.3B | ||
| Q1 25 | $480.0M | $1.3B | ||
| Q4 24 | $490.4M | $1.4B | ||
| Q3 24 | $491.3M | $1.3B | ||
| Q2 24 | $472.4M | $1.2B | ||
| Q1 24 | $467.9M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $51.0M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $50.7M |
| 自由现金流率自由现金流/营收 | 71.6% | 21.2% |
| 资本支出强度资本支出/营收 | 0.2% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.19× | 4.31× |
| 过去12个月自由现金流最近4个季度 | $344.9M | $138.0M |
8季度趋势，按日历期对齐
| Q4 25 | $292.0M | $51.0M | ||
| Q3 25 | $41.6M | $46.2M | ||
| Q2 25 | $41.3M | $50.3M | ||
| Q1 25 | $-27.5M | $-7.4M | ||
| Q4 24 | $-5.2M | $44.0M | ||
| Q3 24 | $8.2M | $18.9M | ||
| Q2 24 | $-1.4M | $-14.0K | ||
| Q1 24 | $-53.7M | $24.8M |
| Q4 25 | $291.2M | $50.7M | ||
| Q3 25 | $40.3M | $46.1M | ||
| Q2 25 | $41.1M | $49.3M | ||
| Q1 25 | $-27.7M | $-8.1M | ||
| Q4 24 | $-5.9M | $43.2M | ||
| Q3 24 | $8.2M | $18.7M | ||
| Q2 24 | $-1.5M | $-122.0K | ||
| Q1 24 | $-53.9M | $24.6M |
| Q4 25 | 71.6% | 21.2% | ||
| Q3 25 | 25.3% | 20.5% | ||
| Q2 25 | 25.2% | 22.9% | ||
| Q1 25 | -19.0% | -3.9% | ||
| Q4 24 | -4.5% | 21.6% | ||
| Q3 24 | 7.0% | 10.1% | ||
| Q2 24 | -1.4% | -0.1% | ||
| Q1 24 | -58.1% | 14.0% |
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | 0.8% | 0.0% | ||
| Q2 25 | 0.1% | 0.5% | ||
| Q1 25 | 0.1% | 0.4% | ||
| Q4 24 | 0.5% | 0.4% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.3% | 0.1% |
| Q4 25 | 1.19× | 4.31× | ||
| Q3 25 | 3.23× | 16.57× | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
WK
| License And Service | $219.3M | 92% |
| XBRL Professional Services | $16.4M | 7% |
| Other Services | $3.2M | 1% |
